Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IIICompletedD-0441-2024

Drug recall · April 24, 2024

NEXLIZET recall

Why: Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.

Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).

The recall

Product

NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03

Lots / codes

Lot #, 1990305, Exp 08-31-2025

Quantity
3,480 30-count bottles
Company
Esperion, Ann Arbor, MI
Distribution
Nationwide in the USA
Initiated
March 27, 2024 · Voluntary: Firm initiated
Classified
April 12, 2024
Reported
April 24, 2024
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Nexlizet

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.